Prevention of stroke for clinical purposes

被引：0

作者：

Grotemeyer, K-H. ^{[1
]}

Grotemeyer, K. C. ^{[1
]}

机构：

[1] Klinikum Saarbrucken, Neurol Klin, D-66119 Saarbrucken, Germany

来源：

NERVENHEILKUNDE | 2009年 / 28卷 / 11期

关键词：

Stroke; secondary prevention; aggregation inhibitors; anti-coagulation; costs; ACETYLSALICYLIC-ACID; SECONDARY PREVENTION; ATRIAL-FIBRILLATION; DOUBLE-BLIND; ASPIRIN; CLOPIDOGREL; TRIAL; RISK; DIPYRIDAMOLE; ATORVASTATIN;

D O I：

10.1055/s-0038-1627161

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The physician knows the guidelines from the German Neurology Society (DGN) for the prevention of a second stroke. However, for the treatment of a patient pragmatism is necessary and the costs for the system have to be regarded. Furthermore, clinical studies can leave unanswered questions. For the choice of the aggregation inhibitor the individual situation of the patient should be regarded. Blood pressure has to be observed and regulated. Lipid-lowering agents are effective for elderly patients as prevention, but not as first choice treatment. For every medical treatment, practical and clinical usefulness should be regarded.

引用

页码：789 / +

页数：6

共 50 条

[31] The new Epoch of Antithrombotic Therapyin the Long-Term Prevention of a non-Cardioembolic Stroke [J].

Fonyakin, A., V ;

Geraskina, L. A. .

KARDIOLOGIYA, 2020, 60 (12) :97-103

[32] European Stroke Prevention - Study 2 - Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke [J].

Diener, H ;

Cunha, L ;

Forbes, C ;

Sivenius, J ;

Smets, P ;

Lowenthal, A .

NERVENHEILKUNDE, 1999, 18 (07) :380-390

[33] Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke [J].

Weber, Ralph ;

Weimar, Christian ;

Diener, Hans-Christoph .

EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (12) :1883-1894

[34] Efficacy of Antiplatelet Treatment in Stroke Prevention: Past, Present, and Future [J].

Lukasik, Maria ;

Owecki, Michal K. .

DRUG DEVELOPMENT RESEARCH, 2013, 74 (07) :428-439

[35] Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke [J].

Ringleb, PA ;

Schwark, C ;

Schwaninger, M ;

Schellinger, PD .

EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (03) :359-367

[36] Clopidogrel for the secondary prevention of stroke [J].

Diener, HC ;

Ringleb, PA ;

Savi, P .

EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (05) :755-764

[37] Secondary prevention of stroke - an update [J].

Forbes, CD .

JOURNAL OF THE ROYAL SOCIETY OF HEALTH, 1998, 118 (01) :15-17

[38] Short- vs. long-termdual antiplatelet therapy in secondary prevention for ischaemic stroke: a network metanalysis [J].

Pugliese, Francesca ;

Arasaratnam, Punitha ;

Moellenberg, Marcus ;

Dani, Sourbha .

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2019, 5 (04) :298-309

[39] Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice [J].

Heidbuchel, Hein ;

Verhamme, Peter .

ACTA CARDIOLOGICA, 2010, 65 (05) :491-497

[40] A Clinical Update on Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke [J].

Katelyn Marsden ;

Hannah Y. Mak ;

C. Patrick Crooks ;

Preethy Pankaj ;

Thuhien Nguyen ;

David Tirschwell .

Current Cardiology Reports, 2021, 23

← 1 2 3 4 5 →